309 related articles for article (PubMed ID: 16260202)
1. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.
Buys SS; Partridge E; Greene MH; Prorok PC; Reding D; Riley TL; Hartge P; Fagerstrom RM; Ragard LR; Chia D; Izmirlian G; Fouad M; Johnson CC; Gohagan JK;
Am J Obstet Gynecol; 2005 Nov; 193(5):1630-9. PubMed ID: 16260202
[TBL] [Abstract][Full Text] [Related]
2. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
[TBL] [Abstract][Full Text] [Related]
3. The role of transvaginal ultrasound in screening for ovarian cancer.
Campbell S; Gentry-Maharaj A
Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
[TBL] [Abstract][Full Text] [Related]
4. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Nyante SJ; Black A; Kreimer AR; Duggan MA; Carreon JD; Kessel B; Buys SS; Ragard LR; Johnson KA; Dunn BK; Lamerato L; Commins JM; Berg CD; Sherman ME
Gynecol Oncol; 2011 Mar; 120(3):474-9. PubMed ID: 21144559
[TBL] [Abstract][Full Text] [Related]
5. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
[TBL] [Abstract][Full Text] [Related]
6. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
Partridge EE; Greenlee RT; Riley TL; Commins J; Ragard L; Xu JL; Buys SS; Prorok PC; Fouad MN
Obstet Gynecol; 2013 Jan; 121(1):25-31. PubMed ID: 23262924
[TBL] [Abstract][Full Text] [Related]
7. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
Temkin SM; Miller EA; Samimi G; Berg CD; Pinsky P; Minasian L
Eur J Cancer; 2017 Dec; 87():182-188. PubMed ID: 29156299
[TBL] [Abstract][Full Text] [Related]
8. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henderson JT; Webber EM; Sawaya GF
JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
[TBL] [Abstract][Full Text] [Related]
9. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer screening in women with a family history of breast or ovarian cancer.
Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P
Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240
[TBL] [Abstract][Full Text] [Related]
12. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
Pinsky PF; Yu K; Kramer BS; Black A; Buys SS; Partridge E; Gohagan J; Berg CD; Prorok PC
Gynecol Oncol; 2016 Nov; 143(2):270-275. PubMed ID: 27615399
[TBL] [Abstract][Full Text] [Related]
13. Abnormal CA-125 levels in menopausal women without ovarian cancer.
Terada KY; Elia J; Kim R; Carney M; Ahn HJ
Gynecol Oncol; 2014 Oct; 135(1):34-7. PubMed ID: 25127988
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Wentzensen N; Black A; Jacobs K; Yang HP; Berg CD; Caporaso N; Peters U; Ragard L; Buys SS; Chanock S; Hartge P
PLoS One; 2011; 6(7):e21731. PubMed ID: 21750727
[TBL] [Abstract][Full Text] [Related]
15. Results from four rounds of ovarian cancer screening in a randomized trial.
Partridge E; Kreimer AR; Greenlee RT; Williams C; Xu JL; Church TR; Kessel B; Johnson CC; Weissfeld JL; Isaacs C; Andriole GL; Ogden S; Ragard LR; Buys SS;
Obstet Gynecol; 2009 Apr; 113(4):775-782. PubMed ID: 19305319
[TBL] [Abstract][Full Text] [Related]
16. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
17. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
[TBL] [Abstract][Full Text] [Related]
19. Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.
Bodelon C; Pfeiffer RM; Buys SS; Black A; Sherman ME
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217774
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
